Novozymes A/s

Novozymes, Inc.

Deborah Yaver

Allan Svendsen

Signe Eskildsen Larsen

Michael Lamsa

Lars Lehmann Hylling Christensen

Michael Skjoet

Peter Colin Gregory

Nina Lundin

The pharmaceutical use of lipases related to the() lipase comprising amino acids 1-269 of SEQ ID NO: 2, optionally in combination with a protease and/or an amylase. Examples of medical indications are: Treatment of digestive disorders, pancreatic exocrine insufficiency (PEI), pancreatitis, cystic fibrosis, diabetes type I, and/or diabetes type II. The lipases of the invention have, e.g., an improved digestion performance in vitro, an improved activity at a pH in the neutral range, an improved stability at low pH, and are stable against protease-degradation, and/or are stable in the presence of pepsin and bile salts. The invention also relates to methods of determining digestion performance in vitro of lipases, as well as to certain novel variants of the lipase of

Lipase variants for pharmaceutical use

Growing community of inventors

Davis, CA, United States of America

Deborah Yaver